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Whole-exome sequencing (WES) studies have
demonstrated the contribution of de novo loss-of-
function single-nucleotide variants (SNVs) to autism
spectrum disorder (ASD). However, challenges in
the reliable detection of de novo insertions and dele-
tions (indels) have limited inclusion of these variants
in prior analyses. By applying a robust indel detec-
tion method to WES data from 787 ASD families
(2,963 individuals), we demonstrate that de novo
frameshift indels contribute to ASD risk (OR = 1.6;
95% CI = 1.0–2.7; p = 0.03), are more common in fe-
male probands (p = 0.02), are enriched among genes
encoding FMRP targets (p = 63 109), and arise pre-
dominantly on the paternal chromosome (p < 0.001).
On the basis of mutation rates in probands versus
unaffected siblings, we conclude that de novo frame-16 Cell Reports 9, 16–23, October 9, 2014 ª2014 The Authorsshift indels contribute to risk in approximately 3% of
individuals with ASD. Finally, by observing clustering
of mutations in unrelated probands, we uncover two
ASD-associated genes: KMT2E (MLL5), a chromatin
regulator, and RIMS1, a regulator of synaptic vesicle
release.INTRODUCTION
Autism spectrum disorder (ASD) is a highly heritable neurodeve-
lopmental syndrome of unknown etiology. An excess of de novo
copy-number variants (CNVs) in affected individuals is well es-
tablished (Levy et al., 2011; Sanders et al., 2011; Sebat et al.,
2007). Moreover, whole-exome sequencing (WES) studies
have demonstrated that de novo loss-of-function (LoF) single-
nucleotide variants (SNVs) also carry a significant risk for ASD
(Iossifov et al., 2012; Neale et al., 2012; O’Roak et al., 2012;
Sanders et al., 2012). Importantly, the observation of multiple
de novo events at the same locus provides a reliable and statis-
tically rigorous method to identify specific variations associated
with ASD (Sanders et al., 2011, 2012; Willsey et al., 2013). This
approach has highlighted the contribution of CNVs at 16p11.2,
15q11.2-13, 22q11.2, 7q11.23, and NRXN1, and (to date)
SNVs in nine genes: ANK2, CHD8, CUL3, DYRK1A, GRIN2B,
KATNAL2, POGZ, SCN2A, and TBR1.
Although the above-cited works and similar studies have been
critically important in outlining the genomic architecture of ASD
(Buxbaum et al., 2012), they have not provided a comprehensive
view of de novo variation in ASD. For example, systematic anal-
ysis of de novo insertions and deletions (indels) in WES data has
been hindered by technological limitations, including mapping
errors and ambiguities in annotation leading to low sensitivity
or infeasible numbers of confirmations.
In this work, we resolved the most pressing issues in the
detection of de novo indels by combining a family-based local
realignment approach (Albers et al., 2011) with empirically
derived quality metric thresholds to dramatically improve the ac-
curacy of de novo indel prediction. We applied this approach,
followed by comprehensive de novo indel confirmation, to previ-
ously analyzedWES data from 2,963 individuals in 787 families in
the Simons Simplex Collection (SSC; Table S1), allowing a reli-
able analysis of the mutation rate in probands versus unaffected
siblings. We identified 44 de novo coding indels and observed a
significant excess of de novo frameshift indels in probands
versus unaffected siblings with an odds ratio (OR) of 1.6, similar
to that observed for de novo LoF SNVs. These additional data al-
lowed us to refine our prior analysis of the contribution of de novo
disruptive events to ASD population risk. We now estimate that
approximately 7% of affected individuals (4% with a de novo
LoF SNV and 3% with a de novo frameshift indel) carry a de
novo disruptive coding mutation that contributes to ASD. More-
over, using our previously described approach to assess the sig-
nificance of clustering of de novo events at genomic loci
(Sanders et al., 2011, 2012; Willsey et al., 2013), we identified
two ASD-associated genes: Lysine (K)-specific methyltransfer-
ase 2E (KMT2E, a.k.a. Mixed-lineage leukemia 5 [MLL5]) and
Regulating synaptic exocytosis 1 (RIMS1), reinforcing prior find-
ings highlighting a role for chromatin modification and synaptic
function in the pathophysiology of ASD.
RESULTS
Identification and Confirmation of De Novo Indels
To assess the burden of de novo indels in ASD, we analyzed
WES data derived from whole-blood DNA from 787 families
(602 quartets and 185 trios) in the SSC (Iossifov et al., 2012;
O’Roak et al., 2012; Sanders et al., 2012; Willsey et al., 2013;
Table S1). Accurate prediction of indels is complicated by
difficulties with alignment (Figure 1B) and multiple possible
representations of the same indel in variant call format (VCF;
Figure 1C). To overcome these difficulties, we developed an
analysis pipeline optimized for de novo indel detection (Fig-
ure 1A) using Dindel local realignment (Albers et al., 2011) to cor-
rect alignment errors, and the LeftAlignIndels tool from GATK
(McKenna et al., 2010) to resolve problems with multiple repre-
sentations of the same variant.Using this approach, we identified a total of 307 putative de
novo indels (258 coding and 49 intronic) in cases and controls.
All 307 were submitted for confirmation by PCR amplification
and Sanger sequencing, blinded to affected status. High-quality
confirmation data were generated for 284 indels (93%), 146 of
which were confirmed as being de novo (119 in coding regions
and 27 in intronic regions), reflecting an overall confirmation
rate of 51% (Table S2). Although a 78% confirmation rate was
achieved with more stringent detection thresholds, there was a
corresponding 18% reduction in indel detection, so we elected
to use the less stringent thresholds to maximize sensitivity.
To further assess the pipeline, we first evaluated our ability to
detect 54 previously confirmed de novo indels within our current
data set (Iossifov et al., 2012; O’Roak et al., 2012). We correctly
identified 52 (96%) of these, and the remaining two indels
were not detected by Dindel in the first step of our pipeline. In
addition, we detected and confirmed six de novo indels in these
samples. Furthermore, use of the latest iteration of GATK re-
sulted in an 8% reduction in indel detection, with no new de
novo indels detected (Table S3). Although the absence of a
gold standard precludes an accurate estimation of sensitivity,
these results suggest that the method outlined in this work
compares favorably with other widely used tools.
In addition to the 59 previously confirmed de novo coding in-
dels in the SSC (Table S2), we confirmed an additional 16 previ-
ously predicted de novo coding indels and identified and
confirmed 44 de novo coding indels.
Increased Burden of De Novo Frameshift Indels in ASD
Probands
In total, we observed and confirmed 119 de novo coding indels
(79 in 787 probands and 40 in 602 unaffected siblings). To assess
the burden of de novo indels in cases versus controls, we relied
solely on the 100 indels detected in 602 quartet families that
included both a proband and an unaffected sibling. We found
47 confirmed de novo indels that altered the reading frame
(frameshift) in probands (0.078 per sample), compared with 30
(0.050 per sample) in siblings (OR = 1.6; 95% confidence interval
[CI]: 1.0–2.7; p = 0.03, one-sidedWilcoxon paired test; Figure 2A;
Table S2). Considering only brain-expressed genes resulted in a
higher OR of 1.7 (95% CI = 1.0–3.0; p = 0.02; Figure 2A; Table
S2). For de novo indels that did not alter the reading frame (in-
frame), no such excess was observed, with 13 (0.022 per sam-
ple) in probands and 10 (0.017 per sample) in siblings (OR =
1.3; 95% CI = 0.5–3.2; p = 0.28, one-sided Wilcoxon paired
test; Figure 2A). Similarly, no excess of intronic de novo indels
was observed in ASD probands versus unaffected sibling con-
trols (Figure S1). We observed a similar burden of frameshift de
novo indels when we applied increasingly stringent quality met-
rics to the 258 putative de novo coding indels instead of visual-
ization and confirmation (Figure S2).
As expected, these results mirrored the previously reported
burden of de novo LoF (nonsense or canonical splice-site)
SNVs (OR = 2.4; 95% CI = 1.3–4.3; p = 0.0002, one-sided Wil-
coxon paired test; Figure 2A), whereas de novo missense
SNVs showed a trend toward overrepresentation in cases
(OR = 1.1; 95% CI = 0.9–1.4; p = 0.07) (Iossifov et al., 2012;
O’Roak et al., 2012; Sanders et al., 2012; Willsey et al., 2013).Cell Reports 9, 16–23, October 9, 2014 ª2014 The Authors 17
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Figure 1. Experimental Overview
(A) Indels were predicted in 787 families from the SSC usingDindel. Throughout the analytical pipeline, probands and siblings are treated equally to allow accurate
assessment of de novo indel burden. Informative SNPs were used to establish the parent of origin of de novo indels.
(B) Alignment errors at the end of reads lead to indels being miscalled as SNVs.
(C) An indel can be represented in multiple ways in VCF files.
See also Tables S1, S2, and S3.Two Genes Show Multiple Independent De Novo LoF
Mutations
Given the similar functional impact of frameshift indels and LoF
SNVs, as well as the similarity between the observed OR and
frequency in ASD cases (Figure 2A), we concluded that we
could treat these mutations as a single class of LoF mutations
when considering the implications of observing multiple de
novo disruptive mutations in the same gene. Using a permuta-
tion test (Sanders et al., 2012) that simulated de novo LoF mu-
tations based on gene size and guanine-cytosine (GC) content
at the rate observed in siblings (0.083 per sample), we found
that a gene with a single disruptive de novo mutation had a
50.4% probability of being associated with ASD (q = 0.496),
whereas a gene with at least two disruptive de novo mutations
had a 97.6% (q = 0.024) probability of being associated
with ASD.
Using this approach, we identified two ASD-associated genes
(Table 1): KMT2E (also called MLL5) Figure 2B) and RIMS1
(Figure 2C).
De Novo Frameshift Indels Support a Role for FMRP
Targets in the Pathophysiology of ASD
The identification of genes that overtly reflected chromatin modi-
fication and synaptic function in ASD led us to evaluate the puta-
tive functions of all 62 unique genes that carried de novo frame-18 Cell Reports 9, 16–23, October 9, 2014 ª2014 The Authorsshift indels in the 787 probands (Table S2). We first assessed
enrichment in Gene Ontology (GO) categories and KEGG path-
ways, as well as for connectivity of protein-protein interaction
networks (DAPPLE). We found no significant results after correc-
tion for multiple comparisons.
We then turned to an assessment of mRNA targets of fragile X
mental retardation protein (FMRP) in light of a recent analysis
that showed enrichment of de novo SNVs in this set of genes
among affected individuals in the SSC (Iossifov et al., 2012).
We assessed the intersection of genes in this study with 842
FMRP targets identified in mouse brain (Darnell et al., 2011)
and 939 FMRP targets identified in human embryonic kidney
293 (HEK293) cells (Ascano et al., 2012); 178 of these targets
are present in both tissue types.
To ensure that factors known to influence de novo mutation
rates did not confound the analysis, we used a generalized linear
model of exome coverage, gene size and GC content, brain
expression, and identification as an FMRP target as predictors
of genes carrying a de novo frameshift indel. We observed a
strong signal for FMRP targets identified in mouse brain, but
not in HEK293 cells (p = 6 3 109, mouse brain; p = 0.13,
HEK293 cells; p = 1 3 106, combined list). No enrichment
was observed for the 29 unique genes with frameshift de novo
indels in siblings (p = 0.55 and p = 0.43 for mouse brain and
HEK293 cells, respectively).
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Figure 2. De Novo Indel Burden and Genes
with Multiple Hits
(A) The rate of denovo indels andSNVs is shown for
602 probands (red) and matched unaffected sib-
lings (blue). ‘‘All’’ refers to all RefSeq genes in hg19.
‘‘Brain’’ refers to the subset of genes that are brain
expressed. ‘‘Nonsense’’ refers to single-nucleotide
substitutions that result in a premature stop codon.
‘‘Splice site’’ refers to single-nucleotide sub-
stitutions that disrupt the canonical splice site.
Error bars represent the 95%CIs andpvalueswere
calculated with a one-sided paired Wilcoxon test.
(B) Two de novo frameshift indels in independent
samples are shown in the geneKMT2E. Both indels
are likely to induce nonsense-mediated decay
(Nagy and Maquat, 1998).
(C) Two de novo frameshift indels in independent
samples are shown in the geneRIMS1. Both indels
are likely to induce nonsense-mediated decay
(Nagy and Maquat, 1998).
See also Figures S1 and S2.We then considered our findings in light of the ASD-associated
spatiotemporal coexpression networks recently reported by our
group (Willsey et al., 2013). Since our prior work relied on over-
lapping sequencing data, including previously reported de
novo indels, here we focused only on the intersection of 18 newly
identified frameshift indels detected in probands. The gene
RIMS1 was found to be present in an ASD-associated network
in the cerebellum and mediodorsal nucleus of the thalamus in
early postnatal life.
Female Probands Have a Greater Burden of De Novo
Frameshift Indels
Female probands have previously been noted to have a higher
burden of de novo CNVs than their male counterparts (Levy
et al., 2011; Sanders et al., 2011); therefore, we assessed the
de novo indel burden by sex. A similar pattern was observed
for de novo frameshift indels in probands, with 0.126 per sample
in the 151 female cases compared with 0.071 per sample in the
636 male cases (OR = 1.9; 95% CI = 1.0–3.4; p = 0.02, one-
sided Wilcoxon unpaired test; Figure 3A). This sex-related
burden was not observed for the de novo in-frame indels
(OR = 0.6; 95% CI = 0.1–3.0; p = 0.68, one-sided Wilcoxon un-
paired test; Figure 3A).
DeNovo Frameshift Indels Are Associatedwith Lower IQ
Given the significant clinical overlap between intellectual
disability (ID) and ASD, and long-standing interest in the relative
contribution of genetic risk to social disability versus ID (Skuse,
2007), we evaluated the relationship between IQ and mutation
status. The presence of a de novo frameshift indel was associ-
ated with a 6.3 point decrement in proband full-scale IQ (FSIQ)
(p < 0.0001, Mann-Whitney U test) compared with probands
with no known de novo LoF indel or SNV. However, de novo
frameshift indels only explained a small fraction of variance in
FSIQ (R2 = 0.004), and 43% of probands with de novo frameshift
indels had FSIQ measures greater than the proband mean of
80.2 (Figure 3B). The current absence of FSIQ data for the par-
ents prevents an analysis of the genetic deviation in FSIQ due
to de novomutations, aswas recently performed for IQ in individ-uals with 16p11.2 CNVs (Zufferey et al., 2012) and for head
circumference in the SSC (Chaste et al., 2013).
De Novo Indels Arise Predominantly from the Paternal
Chromosome
Given the observation that the majority of de novo SNVs arise on
the paternal chromosome (Kong et al., 2012; O’Roak et al.,
2012), we assessed the parent of origin for the de novo indels.
Informative SNPs (i.e., those unique to one parent and trans-
mitted to the child) within 1,000 bp of de novo indels were iden-
tified in WES data. The regions were amplified with PCR and
sequenced on an IlluminaMiSeq. Visual inspection of the data al-
lowed us to determine the parent of origin.
We observed a significant excess of de novo indels arising
from the paternal chromosome (31 paternal versus 4 maternal;
p < 0.001; binomial exact test; Figure 3C), as was observed for
de novo SNVs.
Correlation between Parental Age and De Novo Indels
Multiple prior studies, including our own (Kong et al., 2012;
O’Roak et al., 2012; Sanders et al., 2012), have demonstrated
a robust correlation between paternal age and the rate of de
novo SNVs. Consequently, we tested for this relationship with re-
gard to de novo indels by fitting a linear model with paternal age
(years) at the child’s birth as a predictor for the presence of a de
novo indel. Surprisingly, we found no association with paternal
age (slope b = 0.01, SE ± 0.01, p = 0.33, regression). This result
was not altered by considering maternal age (b = 0.01, p = 0.41),
probands only (b = 0.00, p = 0.89; Figure 3D), or siblings only (b =
0.03, p = 0.12; Figure 3D), or by excluding frameshift indels (b =
0.02, p = 0.34). In comparison, applying the same model to the
de novo SNVs continued to show a robust association for
paternal age (b = 0.02, SE ± 0.01, p = 0.0002) equivalent to an ex-
tra 0.2 de novo coding mutations per decade of the father’s age.
Contribution of De Novo Indels and SNVs to ASD
Population Risk
Based on the observed difference in de novo mutation burden
between cases and controls (Figure 2A), we predict that 3% ofCell Reports 9, 16–23, October 9, 2014 ª2014 The Authors 19
Table 1. Identified De Novo Indels in Genes with Previously Reported De Novo Nonsynonymous Mutations
Gene Sample hg19 Location Variant Effect Source
CHD2 10C100480 chr15:93518170 C->T missense Neale et al., 2012
13618.p1 chr15:93524060 AAAG frameshift Identified herein
KMT2E 14299.p1 chr7:104702706 C frameshift Identified herein
12952.p1 chr7:104748101 C frameshift Iossifov et al., 2012
PHF3 14133.p1 chr6:64413433 CG frameshift Identified herein
14110.p1 chr6:64423242 C->T missense Sanders et al., 2012
RIMS1 13162.p1 chr6:72889392 +A frameshift Iossifov et al., 2012
13497.p1 chr6:73102488 +A frameshift Identified herein
See also Table S2.affected individuals carry de novo risk frameshift indels and an
additional 4% carry de novo risk LoF SNVs. Should an ASD as-
sociation be demonstrated for de novomissense and de novo in-
frame mutations (as is likely with increased power), such muta-
tions would potentially account for a further 7% of ASD
individuals.
DISCUSSION
Our analysis of 787 ASD families from the SSC, including 602
unaffected sibling controls, demonstrates the association of
de novo frameshift indels with ASD. Furthermore, the similar-
ity between the OR and mutation rate observed for de novo
frameshift indels and those observed for de novo LoF SNVs,
as well as the overlap in the functional consequences, fits
with the assumption that de novo frameshift indels and de
novo LoF SNVs can be considered as a single group of high-
ly disruptive mutations. Overall, these disruptive mutations
are predicted to contribute to risk in 7% of the ASD
population.
By reanalyzing WES data from the SSC cohort using this more
sensitive and reliable approach for discovering de novo indels,
we identified two ASD genes: KMT2E (MLL5) and RIMS1.
KMT2E is a chromatin regulator that is recruited to methylated
histones found at the promoters of actively expressed genes,
specifically H3K4me3. It was initially identified as a tumor-sup-
pressor gene and its role in hematopoietic stem cell homeosta-
sis and self-renewal has been well documented. However, the
gene is highly pleiotropic, with roles in cytokinesis, response
to DNA damage, and genome maintenance (Ali et al., 2013).
Although KMT2E has not previously been associated with
neurological disorders, chromatin regulation in fetal develop-
ment has been identified as a key risk factor for ASD (O’Roak
et al., 2012; Willsey et al., 2013) and the gene is highly expressed
throughout the brain, especially during fetal development (Kang
et al., 2011).
RIMS1 is a RAS signaling gene that is essential for multiple
aspects of neurotransmitter release. It plays a role in presynap-
tic plasticity (Kaeser et al., 2012), with mouse knockouts
showing deficits in learning and memory (Powell et al., 2004)
and increased seizure frequency following induced status epi-
lepticus (Pitsch et al., 2012). RIMS1 is expressed throughout
the human brain, with levels increasing throughout develop-20 Cell Reports 9, 16–23, October 9, 2014 ª2014 The Authorsment and reaching a plateau in the third trimester that persists
throughout adulthood (Kang et al., 2011). The gene is present in
an ASD-associated postnatal coexpression network in the cer-
ebellum and mediodorsal nucleus of the thalamus (8-10 MD-
CBC) due to its coexpression with the ASD gene SCN2A (Will-
sey et al., 2013).
The FSIQ was below the proband average of 81 in the SSC
(range 46–74) in all four individuals with mutations in KMT2E and
RIMS1. The anxious/depressed, withdrawn/depressed, somatic
complaints, and thought problems scales of the Child Behavior
Checklist were elevated for both individuals with RIMS1 muta-
tions only. Inconsistent results were observed for other pheno-
typic measures, including seizures and head circumference.
Although the ASD-associated de novo indels do not form a
highly connected protein-protein interaction network or show
enrichment for GO terms, we do confirm the previously docu-
mented enrichment of FMRP target genes carrying de novo
LoF mutations (Iossifov et al., 2012). In light of the strength and
reproducibility of this relationship, the identification of mRNAs
targeted by FMRP in the developing human brain is likely to be
a valuable resource for ASD gene discovery.
Given the observed similarities between de novo frameshift
indels and de novo LoF SNVs, a marked overrepresentation
of mutations on the paternal allele might have been anticipated.
However, we did not observe the expected correlation between
these paternally enriched de novo mutations and paternal age.
Given the relatively small number of indels, it is likely that this
negative result reflects inadequate statistical power. We will
test this hypothesis as substantially larger WES data sets
from ASD families become available in the near future (Bux-
baum et al., 2012).
Finally, we investigated the relationship between de novo
frameshift indels and IQ. Given the association of many estab-
lished ASD mutations with decrements in cognitive functioning
and the frequent phenotypic overlap seen in clinical samples,
there has been speculation that de novo disruptive mutations
may only carry a risk for ID and not for the core social deficits
that define ASD. Our data do not support this hypothesis.
Although we observe lower IQ among probands that carry de
novo frameshift indels compared with probands without any de
novo LoF mutations, the difference is small (6.3 IQ points) and
accounts for only a fraction of the variance in IQ (R2 = 0.004),
and the distribution of IQ is similar to that in other probands
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Figure 3. Sex Difference, Parent of Origin,
and Parental Age
(A) A consistently higher rate of de novo frameshift
indels was observed in female probands (pink)
compared with male probands (blue), but this dif-
ference was not observed in unaffected siblings.
‘‘All’’ describes all de novo frameshift indels and
‘‘Brain’’ indicates only those expressed in the
brain. Error bars represent the 95% CIs and p
values were calculated with a one-sided paired
Wilcoxon test.
(B) Histogram of full-scale IQ in all probands
(green) and probands with a de novo frameshift
indel (red).
(C) The majority of de novo indels for which the
parent of origin could be resolved were found to be
on the paternal (blue) rather than the maternal
(pink) chromosome (p < 0.001; binomial). This
result was observed in both probands and siblings
separately.
(D) No clear relationship between the presence of a
de novo indel and increased paternal age was
observed for probands (green) or siblings (purple);
p valueswere estimatedwith a Poisson regression.(Figure 3B). Moreover, given the emerging picture of shared risks
for de novo SNVs among a wide range of neurodevelopmental
syndromes (Allen et al., 2013; Fromer et al., 2014; Moreno-De-
Luca et al., 2014), the most parsimonious explanation is that a
subset of highly disruptive risk mutations are associated with a
range of phenotypic outcomes, including ID, ASD, schizo-
phrenia, and epilepsy.
Based on current estimates, the detection of de novo frame-
shift indels and LoF SNVs identifies a genetic risk factor in
approximately 7% of affected individuals, rivaling the contribu-
tion of de novoCNVs (Sanders et al., 2011).Moreover, in addition
to confirming important recent observations regarding the
genomic architecture of ASD, including the paternal origin of
the majority of small de novo mutations, the approach is yielding
a growing list of ASD risk genes, pointing to chromatin modifica-
tion, synaptic functioning, and binding to FMRP as key patho-
physiological mechanisms.
EXPERIMENTAL PROCEDURES
Sample Collection and Initial Data Processing
Whole-exome data for 2,963 samples from 787 families (602 quartets and
185 trios) in the SSC were obtained (Table S1). Exome capture was per-
formed using a NimbleGen custom array (N5210) or NimbleGen EZExo-
meV2.0 (N5718) followed by sequencing on Illumina GAIIx or HiSeq2000
instruments. Reads were aligned to hg19 with BWA. This research was re-
viewed by the Yale institutional review board under HIC protocol number
0301024156.Cell Reports 9, 16–2Family-Based De Novo Indel Detection
Indels were predicted in children using Dindel (Alb-
ers et al., 2011) followed by Dindel local realign-
ment for all family members. The LeftAlignIndels
tool fromGATK (McKenna et al., 2010) was applied
to all of the resulting BAM files, and indels were as-
sessed in the realigned files. Rare inherited hetero-
zygous indels were used to set appropriate qualityfilters to identify rare de novo indels, including R10 unique reads in all family
members, indel not observed in other SSC families, and <5% of reads with
an indel in either parent.
Realigned BAM files for the resulting 522 putative de novo coding indels
(0.39 per sample in probands and 0.37 per sample in siblings) were visualized
using Integrative Genome Viewer (IGV) (Thorvaldsdo´ttir et al., 2013) by two in-
dependent researchers who were blinded to affected status. High concor-
dance between the two researchers was observed (kappa coefficient =
0.94) and any indel that was potentially de novo according to either researcher
was submitted for confirmation. In total, 258 indels (50%, 0.27 per sample in
probands and 0.16 per sample in siblings) were selected. In addition, the 49
intronic de novo indels with the best indel quality scores were submitted for
confirmation as an additional control, yielding a total of 307 confirmations.
Indel Confirmations
Indels were confirmed using PCR amplification of whole-blood DNA and
Sanger sequencing. Of 307 putative de novo indels, high-quality confirmation
data were generated for 284 (96%). Of these, no indel was observed in the
child for 44 (15%), while an inherited indel was observed in 93 (33%). One
confirmed indel was observed in both the proband and sibling, but not in either
parent, suggesting germline mosaicism. This left 146 confirmed de novo indels
and a confirmation rate of 51%.
Identifying the Parent of Origin
Informative SNPswithin 1,000 bp of a confirmed de novo indel were identified in
WES data. The regions were amplified fromwhole-blood DNA of the index child
and both parents using PCR. Amplified DNA was normalized using PicoGreen
quantitation and pooled separately for children, fathers, and mothers. Each
pool underwent indexed library preparation and was run on an Illumina MiSeq
with 250bppaired-end reads. Thealigned sequence datawere assessed in IGV.3, October 9, 2014 ª2014 The Authors 21
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